A Simple Key For BCAT-IN-4 Unveiled
MI-CP151 was a stage 1b randomised, double-blind, placebo managed, dose-escalation, multicentre analyze To guage numerous intravenous doses of sifalimumab, in Grownup people with dermatomyositis or polymyositis (NCT00533091). Principal trial targets have been To guage the security and tolerability of sifalimumab in dermatomyositis or polymyositis i